US Edition
September 30, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against NVO - Novo Nordisk (NYSE:NVO)
Shareholders allege Novo Nordisk misled investors with false growth statements, causing a 21.83% stock drop after the company cut its 2025 sales and profit outlook.
- A lawsuit involving a group claim has been initiated against Novo Nordisk A/S, with the deadline to apply for lead plaintiff status set for September 30, 2025.
- The lawsuit follows Novo Nordisk's July 29, 2025 announcement lowering its 2025 sales outlook due to reduced growth expectations for Wegovy and Ozempic.
- Novo attributed the lowered outlook to persistent compounded GLP-1 use, slower market expansion, and increased competition.
- Following the announcement, Novo’s ADR price fell by $15.06 per share, or 21.83%, closing at $53.94 on July 29, 2025.
- Shareholders who purchased Novo securities between May 7 and July 28, 2025, are encouraged to register before the September 30 deadline to seek lead plaintiff status.
56 Articles
56 Articles
September 30, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against NVO - Novo Nordisk (NYSE:NVO)
NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE:NVO). Shareholders who purchased shares of NVO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/novo-nordisk-a-s-loss-s…
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines – NVO
NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Novo Nordisk A/S (“Novo Nordisk”...
Bennington Banner
ATTENTION NYSE: NVO INVESTORS: Contact Berger Montague About a Novo Nordisk A/S Class Action Lawsuit
PHILADELPHIA, Aug. 12, 2025 /PRNewswire/ -- Berger Montague PC is investigating claims under the federal securities laws against Novo Nordisk A/S (NYSE: NVO) ("Novo" or the "Company"), a global pharmaceutical company, headquartered in Denmark, after a class action lawsuit was…
Coverage Details
Bias Distribution
- 56% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
